Investor Relations

AgeneBio is dedicated to developing the first and only treatments designed to address hippocampal overactivity.

Investment Thesis

Novel Pipeline for Neurological and Psychiatric Diseases Addressing Significant Unmet Medical Needs

  • Extensive Phase 3 expertise in Alzheimer’s disease (AD) among R&D leadership team
  • Science recognized as novel and promising by AD experts
  • Phase 3 trial in process
  • Favorable risk/benefit profile for high unmet need disease state
  • Multi-billion dollar revenue potential with lifecycle opportunities

More news releases

AgeneBio in the news

Email Alerts

Sign up for email alerts here.

Investor Contact

Michela Gallagher

Media Contact
Hilary Lefebvre | Acadia Co. | 212.300.4929